Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 6/20 | 0.72 |
| ▸ | DRD2 | P14416 | 2/20 | 0.67 |
| ▸ | DRD4 | P21917 | 2/20 | 0.67 |
| ▸ | DRD3 | P35462 | 2/20 | 0.67 |
| ▸ | HTR1A | P08908 | 4/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.53 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | PDE2A | O00408 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13375737 | 0.87 | MPO (0.69) | MPODRD2DRD4DRD3HTR1A | |
| SCHEMBL13374358 | 0.86 | MPO (0.67) | MPODRD2DRD4DRD3HTR1A | |
| SCHEMBL5170221 | 0.85 | MPO (0.77) | MPODRD2DRD4DRD3HTR1A | |
| SCHEMBL13499605 | 0.84 | MPO (1.00) | MPODRD2DRD4DRD3HTR1A | |
| SCHEMBL9635445 | 0.82 | MPO (0.73) | MPODRD2DRD4DRD3HTR1A | |
| SCHEMBL13504100 | 0.81 | DRD2 (1.00) | DRD2DRD4DRD3MAPK1L3MBTL1 | |
| SCHEMBL23179558 | 0.76 | ACHE (0.51) | DRD2DRD4DRD3PDE2A | |
| SCHEMBL6695064 | 0.75 | DRD2 (0.67) | MPODRD2DRD4DRD3HTR1A | |
| SCHEMBL5198405 | 0.75 | DRD2 (0.71) | MPODRD2DRD4DRD3HTR1A | |
| SCHEMBL13499597 | 0.75 | SLC6A4 (0.69) | MPOHTR1ASLC6A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | CXCR4, CXCR1, CXCR3 | MPO 414/4885DRD2 2462/4885DRD4 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.